Emerald Holding, Inc. Fourth Quarter & FY 2025 March 13, 2026 Legal Disclaimer Forward-Looking Statements The information provided in this presentation is for general informational purposes only. This presentation contains certain forward-looking statements regarding Emerald Holding, Inc. and its subsidiaries (the "Company"), including, but not limited to, general economic conditions, including the impact of tariffs and trade policy or more specifically about the markets in which the Company operates, inclu ...

Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical ...

Fourth Quarter 2025 Earnings Presentation Contents Contents Performance Highlights Financial Highlights Operational Highlights Appendix Performance Highlights Performance Highlights Net Revenues 1,141 5.4 RMB million Gross Profit 358 RMB million 158 RMB million 2025 Q4 By harmonizing organic business development with targeted strategic investment, we have established a resilient framework for scale. Effective execution drove meaningful progress in our international expansion, while intensified customs enfor ...

VEON Delivers Record Digital Growth Revenues +9.9% in 2025, +17.4% in 4Q25 EBITDA +18.8% in 2025, +29.1% in 4Q25 Digital Revenues +63% in 2025, +84% in 4Q25 13 March 2026 | FY25 & 4Q25 Results Presentation DISCLAIMER Notice To Readers Certain of VEON's results and other financial information presented in this document are, unless otherwise stated, prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the international Accounting Standards Board and have not been exter ...

INVESTOR PRESENTATION March 2026 Forward Looking Statements This presentation contains certain forward-looking statements, including without limitation, statements concerning the Company's operations, economic performance and financial condition. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are developed by combining currently available information with the Company's beliefs and assumption ...

Savara Inc. ("Savara" or the "Company") cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements regarding the potential health benefits and risks and projected development timeline of MOLBREEVI; the timing of regulatory submissions; the potential for ...

Investor Presentation March 2026 SAFE HARBOR STATEMENT This presentation contains highly confidential and proprietary information regarding Innovative Solutions & Support, Inc. (Nasdaq: ISSC) dba Innovative Aerosystems and its subsidiaries ("IA or the "Company") and their strategy and organization. This confidential presentation is provided to you on the condition that you agree that you will hold it in strict confidence and not reproduce, disclose, forward or distribute it to any third party in whole or in ...

OWENS CORNING Q1 2026 INVESTOR PRESENTATION This presentation shared at the following events: | 03/11/26 | IR Roadshow Hosted by Deutsche Bank – Baltimore | | --- | --- | | | Brian Chambers, Chair & Chief Executive Officer | | 03/05/26 | Wolfe Research Housing Conference – New York | | | Todd Fister, Chief Financial Officer | | 03/04/26 | Evercore ISI Housing and Building Products Symposium – New York | | | Todd Fister, Chief Financial Officer | TM FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES This prese ...

1 Medicines for the Brain Corporate Presentation March 2026 NASDAQ: CRVO Forward-Looking Statements This presentation includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the CervoMed Inc. (Company), including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic eff ...

Barinthus Biotherapeutics Corporate Presentation Guiding the Immune System to Cure Disease March 2026 Nasdaq: BRNS Disclosure Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of federal securities laws, including the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Clywedog and Barinthus Bio, in light of h ...